Wire · opportunities
LSD Just Beat Phase 3 Twice. Now Comes the Hard Part.
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 15 August 2026 · Fusion42 review
Definium Therapeutics’ LSD formulation (DT120) has cleared Phase 3 trials for both major depressive disorder and generalized anxiety disorder, marking a pivotal milestone for psychedelic clinical validation. The main challenges now are practical: session length demands, integration into clinical practice, and reaching underrepresented patient populations, particularly in anxiety treatment.
This Wire brief sits within Fusion42's coverage of Health.
◆ ◆ The Wire takeaway
You face a new operational hurdle as psychedelic therapies move from trials to clinics: the long LSD session times challenge existing reimbursement and care models. Now is the time to build protocols and support systems that make extended psychedelic treatments feasible and accessible, or risk falling behind in mental health innovation.
◆ Coverage
1 source · 15 Aug 2026
◆ Related on Wire
◆ Topics